Ascendis Pharma
$227.87Change from previous close: +0.25%Absolute change: +$0.56
At a glance
- Revenue growth
- +98.03%
- 2025 vs 2024
- Net margin
- -31.7%
- 2024: -104.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 339 | 247 | 248 | 214 | 158 | — |
| Cost of revenue | 27.7 | 17.5 | 23.6 | 22.4 | 31.4 | — |
| Gross profit | 312 | 229 | 224 | 191 | 127 | — |
| Selling, general and administrative | 172 | 145 | 135 | 112 | 106 | — |
| Research and development | 75.9 | 59.0 | 78.2 | 66.9 | 72.0 | — |
| Operating income | 220 | 24.8 | 6.4 | 11.0 | -53.0 | — |
| EBIT | 244 | 19.1 | -6.2 | -37.7 | -15.5 | — |
| EBITDA | 249 | 23.3 | -1.3 | -33.6 | -11.2 | — |
| Interest expense | 14.2 | 67.3 | 20.5 | 19.7 | 19.5 | — |
| Pre-tax income | 230 | -48.2 | -26.7 | -57.4 | -35.0 | — |
| Income tax | 23.1 | -678 | 6.9 | 3.6 | 3.8 | — |
| Net income | 207 | 629 | -33.6 | -61.0 | -38.9 | — |
| Net income to common shareholders | 207 | 629 | -33.6 | -61.0 | -38.9 | — |
| Basic EPS | 3.22 | 10.20 | -0.55 | -1.00 | -0.64 | — |
| Diluted EPS | 2.83 | 9.75 | -0.55 | -1.00 | -0.82 | — |
| Average shares (basic) | 64.3 | 61.7 | 61.0 | 60.8 | 60.5 | — |
| Average shares (diluted) | 68.3 | 64.5 | 61.0 | 60.8 | 63.9 | — |